Literature DB >> 9355069

Reversible glomerular hypertrophy in adult patients with primary focal segmental glomerulosclerosis.

K Nishimoto1, H Shiiki, T Nishino, H Uyama, M Iwano, K Dohi.   

Abstract

The present study was performed to assess the pathogenetic role of glomerular hypertrophy in patients with primary focal segmental glomerulosclerosis (FSGS). We studied 14 patients with FSGS by morphometry. In seven patients, minimal change nephrotic syndrome (MCNS) was diagnosed on the first renal biopsy, but FSGS was diagnosed on the second biopsy (MCNS-FSGS group). Seven other patients with FSGS on the first biopsy underwent second biopsies while in remission (FSGS-R group). Biopsy results were compared with biopsies from 10 patients with MCNS and seven control subjects. Nonsclerotic glomeruli were examined. The mean glomerular tuft area, whole glomerular area, and number of mesangial cells were significantly increased in both biopsies from the MCNS-FSGS group and in the first biopsies obtained during the nephrotic stage of the FSGS-R group, compared with control subjects and patients with MCNS. Biopsies from FSGS patients in remission showed that the mean glomerular tuft area and number of mesangial cells were significantly decreased. The fractional extracellular matrix area (extracellular matrix area/glomerular tuft area) and mesangial cell density (mesangial cell number/glomerular tuft area) in FSGS during both nephrotic and remission stages were the same as those in control subjects and patients with MCNS. The present study suggests that glomerular hypertrophy precedes the development of glomerulosclerosis in FSGS and is reversible when patients are in remission. These features support the pathogenetic importance of glomerular hypertrophy in patients with primary FSGS.

Entities:  

Mesh:

Year:  1997        PMID: 9355069     DOI: 10.1681/ASN.V8111668

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  5 in total

1.  Kidney enlargement effect of angioplasty for nonatherosclerotic renovascular disease: reversibility of ischemic kidney.

Authors:  Tomoyuki Iwasaki; Eikan Mishima; Takehiro Suzuki; Koichi Kikuchi; Takafumi Toyohara; Kazumasa Seiji; Kei Takase; Mariko Miyazaki; Hideo Harigae; Sadayoshi Ito; Takaaki Abe
Journal:  Hypertens Res       Date:  2020-05-22       Impact factor: 3.872

2.  Clinicopathological assessment of the nephron number.

Authors:  Nobuo Tsuboi; Go Kanzaki; Kentaro Koike; Tetsuya Kawamura; Makoto Ogura; Takashi Yokoo
Journal:  Clin Kidney J       Date:  2014-03-11

3.  Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8.

Authors:  Yumi Takiyama; Toshihiro Sera; Masanori Nakamura; Kanaki Ishizeki; Yasuaki Saijo; Tsuyoshi Yanagimachi; Manami Maeda; Ryoichi Bessho; Takao Takiyama; Hiroya Kitsunai; Hidemitsu Sakagami; Daisuke Fujishiro; Yukihiro Fujita; Yuichi Makino; Atsuko Abiko; Masato Hoshino; Kentaro Uesugi; Naoto Yagi; Tsuguhito Ota; Masakazu Haneda
Journal:  EBioMedicine       Date:  2018-10-12       Impact factor: 8.143

4.  The number of nephrons in different glomerular diseases.

Authors:  Davide Viggiano; Michelangelo Nigro; Francesco Sessa; Graziano Vignolini; Riccardo Campi; Sergio Serni; Rosa Maria Pollastro; Gianfranco Vallone; Giuseppe Gigliotti; Giovambattista Capasso
Journal:  PeerJ       Date:  2019-09-04       Impact factor: 2.984

5.  Bowman Capsule Volume and Related Factors in Adults With Normal Renal Function.

Authors:  Takaya Sasaki; Nobuo Tsuboi; Kotaro Haruhara; Yusuke Okabayashi; Go Kanzaki; Kentaro Koike; Akimitsu Kobayashi; Izumi Yamamoto; Makoto Ogura; Takashi Yokoo
Journal:  Kidney Int Rep       Date:  2017-10-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.